Skip to content
Screener
Q3 '26Q2 '26Q1 '26Q2 '25
$4.22M—$6.31M-37.7%$7.22M-18.1%$10.13M—
$82.25M—$64.33M+7.7%$57.81M+23.5%$59.74M—
$13.47M—$13.6M+29.0%$13.52M+33.3%$10.55M—
$95.73M—$77.93M+10.9%$71.34M+25.2%$70.28M—
-$91.51M—-$71.61M-19.1%-$64.11M-33.1%-$60.15M—
-2,168.4%—-1,134.2%-540pp-887.5%-341pp-593.8%—
$192K—$155K-49.5%$182K-50.5%$307K—
$3.9M—$4.41M+27.8%$2.43M-37.7%$3.45M—
-$87.61M—-$67.2M-18.5%-$61.69M-39.4%-$56.7M—
$49K—$53K+20.5%$28K-50.0%$44K—
-$87.66M—-$67.26M-28.3%-$61.45M-47.4%-$52.43M—
-2,077.2%—-1,065.2%-548pp-850.6%-378pp-517.6%—
-$0.68—-$0.52+73.2%-$1.07+34.0%-$1.94—
-$87.81M—-$68.41M-20.3%-$60.84M-36.0%-$56.85M—
-2,080.7%—-1,083.5%-522pp-842.2%-335pp-561.2%—
-$91.51M—-$71.61M-19.1%-$64.11M-33.1%-$60.15M—

FAQ

Where does Generate Biomedicines, Inc.'s income statement data come from?
Every line is extracted from Generate Biomedicines, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.